Aprea Therapeutics, Inc. (APRE) Research

Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Market snapshot

Symbol
APRE
Price
$0.72
Day change
-8.31%
Market cap
$4.6M
P/E ratio
-0.46x
52-week range
0.548-2.22
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Acurx Pharmaceuticals, Inc. (ACXP)
  • Adial Pharmaceuticals, Inc. (ADIL)
  • Aptevo Therapeutics Inc. (APVO)
  • BioCardia, Inc. (BCDA)
  • Creative Medical Technology Holdings, Inc. (CELZ)
  • Galecto, Inc. (GLTO)
  • HCW Biologics Inc. (HCWB)
  • IN8bio, Inc. (INAB)

Recent insider activity

  • Grissinger Michael — A-Award (12555 shares) on 2026-06-16
  • Grissinger Michael — A-Award (3135 shares) on 2026-06-16
  • Gruia Gabriela — A-Award (12555 shares) on 2026-06-16
  • Gruia Gabriela — A-Award (3135 shares) on 2026-06-16
  • Peters Richard — A-Award (12555 shares) on 2026-06-16

Open Aprea Therapeutics, Inc. (APRE) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.